Science

The Science behind IMTV014, A Therapeutic Vaccine for HIV

IMTV014 is in a research and development stage and will not be commercially available until it obtains regulatory approvals such as the ones from US FDA.

IMTV014 is unique.

IMTV014 is a therapeutic AIDS vaccine thus it is designed to be given to patients already infected with the HIV virus. IMTV014 utilizes a recombinant live HIV-1 virus weakened by a deletion of the nef gene of HIV. The nef gene has been shown to be primarily responsible for the ability of the HIV to successfully evade the body's immune response. The deletion of the nef gene enables infected cells to present vaccine HIV antigens in conjunction with surface proteins thus activating CD8 cytotoxic T lymphocytes to kill and clear the virus. IMTV014 allows the body to reestablish and reinvigorate the immune response in order to arrest the disease to achieve remission. The virus is rendered non-pathogenic by using genetic recombinant techniques, the basis of some of the Company's international patents and patent applications. Furthermore, the processing of conserved internal killer-cell recognition sites allows protection against virtually all the different clades of HIV resulting from mutations.

For more information on the basics of vaccines in general and IMTV014 in particular, please visit our FAQ page for IMTV014.